Outlook Therapeutics Inc. (OTLK) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, OTLK scores 38 out of 100 with a letter grade of D- and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Pillar scores are: Fundamental Cash Engine 8/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow 11/20 (institutional accumulation and options positioning), Insider Conviction 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 8/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 8/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillar is insider conviction at 3/20, which means the rating finds little insider-side support for the thesis. The cash-engine pillar at 8/20 reflects negative return on invested capital and a 0% FCF yield, so the rating does not credit current cash generation as a valuation anchor. The forensic pillar at 8/20 pairs an Altman Z of 2.5 with a Piotroski F of 2/9, a combination the rating reads as weak financial health. The one relative strength is the 11/20 whale-flow pillar, which indicates institutional accumulation and options positioning are the main offsetting signal. Valuation tradeoffs are difficult to assess because P/E, forward P/E, EV/EBITDA, and EPS are not available in source data; upside would depend on factors outside the reported financials.

Outlook Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, its market capitalization is $0.1B. The source data does not describe its specific products, customers, or revenue model beyond the reported revenue figures in the SEC financials. Per the SEC financials, FY 2025 revenue was $1.4M against FY 2024 and FY 2023 revenue of $0.0M.

Per the market data, gross margin is 4%, operating margin is -60%, net margin is -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. The reported periods show operating losses in each year and negative free cash flow throughout. Cash rose from $5.7M to $8.7M between FY 2024 and FY 2025 while losses persisted, and FY 2023 cash is not available in source data. Debt is not available in source data for any period.

Per the recent news and catalysts section, the headlines include the appointment of Greg DiPasquale as Chief Commercial Officer, described in one item as ahead of the LYTENAVA U.S. launch. A second item reports two reported owners sharing voting power over a stake above 5%. A third item reports that certain common stock is subject to a lock-up agreement ending on 12-OCT-2026, which is a dated overhang to monitor. Other items are estimates and appointment-related coverage from multiple outlets, each tagged with a YELLOW light and MARKET WIRE impact label. Per the Butterfly Supply-Chain Graph, the supply-chain field is NONE, there are no butterfly links, and there are no proprietary signals.

• What is the company's product pipeline and revenue source behind the FY 2025 revenue of $1.4M, and does the LYTENAVA launch referenced in the news alter that trajectory?
• What are the debt and EPS figures for each reported period, since both are marked N/A in the SEC financials?
• What is the cash runway implied by the FY 2025 cash of $8.7M against the FY 2025 FCF of $-51.8M, and what funding is planned?
• What are the terms and share count implications of the lock-up expiring 12-OCT-2026 and the reported shared voting power over a stake above 5%?